This activity is provided by Med Learning Group.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Copyright © 2024 Med Learning Group. Built by Divigner. All Rights Reserved.
Use of Immunotherapy for Advanced Melanoma: Integrating Patient-Centric and Multidisciplinary Strategies
PROGRAM CHAIR
Meredith McKean, MD, MPHÂ
Director, Melanoma and Skin Cancer Research
Sarah Cannon Research Institute
Nashville, TN
PROGRAM OVERVIEW
This interactive enduring activity is designed to help you optimize the development of treatment plans for your patients with advanced melanoma. Specifically, this program will provide a comprehensive review of the latest data on current and emerging immunotherapy approaches, and of effective strategies to mitigate and manage immunotherapy-associated adverse events. It will also share, expert appraisals of new treatment approaches through multiple clinical case scenarios, illustrative animations, and didactic presentations. Our goal is also to emphasize the importance of shared decision making while maintaining the patient’s well-being.
TARGET AUDIENCE
This enduring activity is designed to meet the educational needs of oncologists, dermatologists, nurse practitioners, oncology pharmacists, and physician assistants who provide care for patients with advanced melanoma.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Select first-line treatment for patients with unresectable or metastatic melanoma based on multidisciplinary consideration of evidence-based guidelines, the most updated immunotherapy clinical trial data, and shared decision making with the patient
- Apply best practices for overall management of adverse events experienced by patients receiving single-agent or combination immunotherapy for unresectable or metastatic melanoma
- Discuss ongoing clinical trials of combination immunotherapy strategies for melanoma, as well as their available data
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Meredith McKean, MD | Dr. McKean discloses that she is a consultant for Castle Biosciences, IQVIA, Merck, Moderna, and Pfizer. She has conducted research for AADI Bioscience, Alpine Immune Sciences, Arcus Biosciences, Arvinas, Ascentage Pharma Group, ASCO, Astellas, Aulos Bioscience, Bayer, Bicycle Therapeutics, BioMed Valley Discoveries, BioNTech, Boehringer Ingelheim, Bristol-Myers Squibb, C4 Therapeutics, Daiichi Sankyo, Dragonfly Therapeutics, EMD Serono, Epizyme, Erasca, Exelixis, Foghorn Therapeutics, G1 Therapeutics, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, IconOVir Bio, IDEAYA Biosciences, Ikena Oncology, ImmVira Pharma, Infinity Pharmaceuticals, Jacobio Pharmaceuticals, Jazz Pharmaceuticals, KeChow Pharma, Kezar Life Sciences, Kinnate BioPharma, Krystal Biotech, MedImmune, Mereo BioPharma, Metabomed, Moderna, NBE Therapeutics, Nektar, Novartis, NucMito Pharmaceuticals, OncoC4, Oncorus, OnKure Therapeutics, PACT Pharma, Pfizer, Plexxikon, Poseida Therapeutics, Prelude Therapeutics, Pyramid Biosciences, Regeneron, Remix Therapeutics, Sapience Therapeutics, Scholar Rock, Seattle Genetics, Synthorx, Takeda Pharmaceuticals, Teneobio, Tempest Therapeutics, Tizona Therapeutics, Tmunity Therapeutics, TopAlliance Biosciences, and Xilio Therapeutics. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Shannon Mutch, MS, RN, OCN, has nothing to disclose.
- Robert M. Geist, MD, MA, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator, for Med Learning Group, has nothing to disclose.
- Jacquelyn Sandfort, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: June 28, 2024
EXPIRATION DATE: June 28, 2025
Copyright ©2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.